-
1 Comment
Shield Therapeutics plc is currently in a long term downtrend where the price is trading 25.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Based on the above factors, Shield Therapeutics plc gets an overall score of 1/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | GB00BYV81293 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Beta | 1.44 |
---|---|
Market Cap | 30M |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1JS.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025